PNC Financial Services Group Inc. Purchases 4,627 Shares of Agilent Technologies, Inc. (NYSE:A)

PNC Financial Services Group Inc. increased its position in shares of Agilent Technologies, Inc. (NYSE:A) by 2.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 172,458 shares of the medical research company’s stock after buying an additional 4,627 shares during the quarter. PNC Financial Services Group Inc. owned 0.06% of Agilent Technologies worth $23,977,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. MV Capital Management Inc. increased its position in shares of Agilent Technologies by 120.7% during the 4th quarter. MV Capital Management Inc. now owns 192 shares of the medical research company’s stock worth $27,000 after purchasing an additional 105 shares during the last quarter. VisionPoint Advisory Group LLC acquired a new position in shares of Agilent Technologies during the 4th quarter worth approximately $29,000. Baystate Wealth Management LLC increased its position in shares of Agilent Technologies by 107.3% during the 4th quarter. Baystate Wealth Management LLC now owns 257 shares of the medical research company’s stock worth $36,000 after purchasing an additional 133 shares during the last quarter. Rosenberg Matthew Hamilton increased its position in shares of Agilent Technologies by 51.1% during the 4th quarter. Rosenberg Matthew Hamilton now owns 284 shares of the medical research company’s stock worth $39,000 after purchasing an additional 96 shares during the last quarter. Finally, Turtle Creek Wealth Advisors LLC acquired a new position in shares of Agilent Technologies during the 4th quarter worth approximately $39,000.

Insider Buying and Selling

In related news, CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $130.00, for a total transaction of $254,540.00. Following the completion of the sale, the chief executive officer now directly owns 25,185 shares in the company, valued at approximately $3,274,050. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $130.00, for a total transaction of $254,540.00. Following the completion of the sale, the chief executive officer now directly owns 25,185 shares in the company, valued at approximately $3,274,050. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Philip Binns sold 2,827 shares of the company’s stock in a transaction on Monday, March 25th. The stock was sold at an average price of $147.54, for a total value of $417,095.58. Following the sale, the senior vice president now owns 9,997 shares of the company’s stock, valued at $1,474,957.38. The disclosure for this sale can be found here. Insiders sold a total of 19,785 shares of company stock worth $2,670,836 in the last ninety days.

Agilent Technologies Stock Performance

NYSE:A opened at $131.81 on Tuesday. The stock has a fifty day moving average price of $140.66 and a 200-day moving average price of $138.24. The company has a market cap of $38.46 billion, a price-to-earnings ratio of 31.16, a PEG ratio of 4.40 and a beta of 1.07. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.64 and a current ratio of 2.15. Agilent Technologies, Inc. has a fifty-two week low of $96.80 and a fifty-two week high of $155.35.

Agilent Technologies (NYSE:A) last released its earnings results on Wednesday, May 29th. The medical research company reported $1.22 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.03. The firm had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.58 billion. Agilent Technologies had a return on equity of 26.25% and a net margin of 18.84%. The company’s revenue was down 8.4% compared to the same quarter last year. During the same period in the prior year, the company posted $1.27 EPS. As a group, equities analysts anticipate that Agilent Technologies, Inc. will post 5.25 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 24th. Investors of record on Tuesday, July 2nd will be given a dividend of $0.236 per share. The ex-dividend date is Tuesday, July 2nd. This represents a $0.94 annualized dividend and a dividend yield of 0.72%. Agilent Technologies’s dividend payout ratio is currently 22.22%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Stifel Nicolaus decreased their target price on Agilent Technologies from $163.00 to $151.00 and set a “buy” rating on the stock in a report on Thursday, May 30th. JPMorgan Chase & Co. decreased their target price on Agilent Technologies from $165.00 to $155.00 and set an “overweight” rating on the stock in a report on Thursday, May 30th. Oppenheimer boosted their target price on Agilent Technologies from $67.00 to $90.00 and gave the stock an “outperform” rating in a report on Tuesday, March 26th. Bank of America reissued a “neutral” rating and set a $134.00 target price (down from $145.00) on shares of Agilent Technologies in a report on Thursday, May 30th. Finally, Citigroup decreased their target price on Agilent Technologies from $145.00 to $135.00 and set a “neutral” rating on the stock in a report on Thursday, May 30th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, Agilent Technologies currently has an average rating of “Moderate Buy” and an average target price of $136.50.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.